Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient
-
- Tawara Junsuke
- Department of General Medicine, Chiba University Hospital, Japan
-
- Uehara Takanori
- Department of General Medicine, Chiba University Hospital, Japan
-
- Sakao Seiichiro
- Department of Respiratory Medicine, Chiba University Hospital, Japan
-
- Igari Hidetoshi
- Department of Infectious Diseases, Chiba University Hospital, Japan
-
- Taniguchi Toshibumi
- Department of Infectious Diseases, Chiba University Hospital, Japan
-
- Kasai Hajime
- Department of Respiratory Medicine, Chiba University Hospital, Japan
-
- Takayanagi Shin
- Department of Infectious Diseases, Chiba University Hospital, Japan
-
- Yahaba Misuzu
- Department of Infectious Diseases, Chiba University Hospital, Japan
-
- Shimada Ryo
- Department of General Medicine, Chiba University Hospital, Japan
-
- Ikusaka Masatomi
- Department of General Medicine, Chiba University Hospital, Japan
Search this article
Abstract
<p>A 55-year-old Japanese man was hospitalized with the novel coronavirus disease 2019 (COVID-19). On the 14th day after the start of favipiravir administration, the patient developed a fever with a temperature of 38.1°C. His pulse rate also became elevated to 128 bpm, so relative bradycardia was not suspected. Since he was in good overall health and no concomitant symptoms and signs were apparent, we considered it to be drug fever due to favipiravir. After the completion of favipiravir treatment, the patient's temperature normalized within 24 hours. We herein report this case of drug fever caused by favipiravir. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 60 (7), 1115-1117, 2021-04-01
The Japanese Society of Internal Medicine